New kernel-based test and fast tests for testing whether two samples are from the same distribution. They work well particularly for high-dimensional data.
      Song, H. and Chen, H. (2023) 
      <arXiv:2011.06127>.

A shiny app to visualize the knowledge networks for the code concepts. Using co-occurrence matrices of EHR codes from Veterans Affairs (VA) and Massachusetts General Brigham (MGB), the knowledge extraction via sparse embedding regression (KESER) algorithm was used to construct knowledge networks for the code concepts. Background and details about the method can be found at Chuan et al. (2021) <doi:10.1038/s41746-021-00519-z>.

Fits keyword assisted topic models (keyATM) using collapsed Gibbs samplers. The keyATM combines the latent dirichlet allocation (LDA) models with a small number of keywords selected by researchers in order to improve the interpretability and topic classification of the LDA. The keyATM can also incorporate covariates and directly model time trends. The keyATM is proposed in Eshima, Imai, and Sasaki (2024) <doi:10.1111/ajps.12779>.

We developed a package 'Keyboard' for designing single-agent, drug-combination, or phase I/II dose-finding clinical trials. The 'Keyboard' designs are novel early phase trial designs that can be implemented simply and transparently, similar to the 3+3 design, but yield excellent performance, comparable to those of more-complicated, model-based designs (Yan F, Mandrekar SJ, Yuan Y (2017) <doi:10.1158/1078-0432.CCR-17-0220>, Li DH, Whitmore JB, Guo W, Ji Y. (2017) <doi:10.1158/1078-0432.CCR-16-1125>,  Liu S, Johnson VE (2016) <doi:10.1093/biostatistics/kxv040>, Zhou Y, Lee JJ, Yuan Y (2019) <doi:10.1002/sim.8475>, Pan H, Lin R, Yuan Y (2020) <doi:10.1016/j.cct.2020.105972>). The 'Keyboard' package provides tools for designing, conducting, and analyzing single-agent, drug-combination, and phase I/II dose-finding clinical trials. For more details about how to use this packge, please refer to Li C, Sun H, Cheng C, Tang L, and Pan H. (2022) "A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs". Manuscript submitted for publication.